Lanean...
Managing hyperparathyroidism in hemodialysis: role of etelcalcetide
Secondary hyperparathyroidism (SHPT) is common in patients receiving maintenance hemodialysis and is associated with adverse outcomes. Currently, SHPT is managed by reducing circulating levels of phosphate with oral binders and parathyroid hormone (PTH) with vitamin D analogs and/or the calcimimetic...
Gorde:
| Argitaratua izan da: | Int J Nephrol Renovasc Dis |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5804266/ https://ncbi.nlm.nih.gov/pubmed/29440923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJNRD.S128252 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|